**Supplementary Table 1:** Cancer types.

|  |  |  |
| --- | --- | --- |
| **Type of Cancer** | **No. of patients (%)** | **Solid cancer or Hematologic malignancy** |
| Lung | 21 (12) | Solid cancer |
| Colorectal | 17 (10) | Solid cancer |
| Breast | 15 (9) | Solid cancer |
| Pancreatic | 14 (8) | Solid cancer |
| Gastric | 10 (6) | Solid cancer |
| Kidney | 10 (6) | Solid cancer |
| Oral cavity and pharyngeal | 9 (5) | Solid cancer |
| Prostate | 9 (5) | Solid cancer |
| Esophageal | 8 (5) | Solid cancer |
| Intrahepatic bile duct | 5 (3) | Solid cancer |
| Uveal | 4 (2) | Solid cancer |
| Bladder | 4 (2) | Solid cancer |
| Laryngeal | 3 (2) | Solid cancer |
| Cancer of unknown primary | 3 (3) | Solid cancer |
| Soft tissue sarcoma | 3 (2) | Solid cancer |
| Uterine | 2 (2) | Solid cancer |
| Salivary gland | 2 (1) | Solid cancer |
| Skin melanoma | 2 (1) | Solid cancer |
| Cervical | 2 (1) | Solid cancer |
| Ovarian | 2 (1) | Solid cancer |
| Fallopian | 1 (1) | Solid cancer |
| Anal | 1 (<1) | Solid cancer |
| Mesothelioma | 1 (<1) | Solid cancer |
| Penile | 1 (<1) | Solid cancer |
| Vaginal | 1 (<1) | Solid cancer |
| Vulvar | 1 (<1) | Solid cancer |
| Pseudomyxoma peritonei | 1 (<1) | Solid cancer |
| Lacrimal gland | 1 (<1) | Solid cancer |
| Thyroid gland | 1 (<1) | Solid cancer |
| Multiple Myeloma | 9 (5) | Hematological malignancy |
| Non-Hodgkin’s lymphoma | 4 (2) | Hematological malignancy |
| Acute myeloid leukemia | 2 (1) | Hematological malignancy |

**Supplementary Table 2A:** Best predictive cut-offs for the ability to walk in the last week, in the last month and for the 4m gait speed test.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Best cut off (no. of days)** | **p-value**  **log rank test** | **AUC (95% CI)** |
| **No. of days able to walk 4m in the last week** | | | |
| 1-month follow-up | ≥2 | **0.001** | 0.58 (0.49-0.67) |
| 2-month follow-up | ≥2 | **0.002** | 0.65 (0.55-0.74) |
| 3-month follow-up | ≥2 | **0.001** | 0.60 (0.51-0.69) |
| 6-month follows-up | ≥2 | **0.005** | 0.58 (0.47-0.69) |
| 12-month follow-up | ≥2 | **<0.001** | 0.60 (0.49-0.71) |
| Entire follow-up | ≥2 | **0.004** | 0.52 (0.38-0.66) |
| **No. of days able to walk 4m in the last month** | | | |
| 1-month follow-up | ≥14 | **0.003** | 0.58 (0.49-0.67) |
| 2-month follow-up | ≥14 | **0.002** | 0.57 (0.48-0.66) |
| 3-month follow-up | ≥14 | **0.001** | 0.60 (0.51-0.69) |
| 6-month follow-up | ≥14 | **0.003** | 0.58 (0.47-0.69) |
| 12-month follow-up | ≥14 | **<0.001** | 0.60 (0.49-0.72) |
| Entire follow-up | ≥14 | **<0.001** | 0.53 (0.39-0.67) |
| **4m gait speed (meter per second)** | | | |
| 1-month follow-up | ≥0.50 m/s | **<0.001** | 0.61 (0.52-0.69) |
| 2-month follow-up | ≥0.50 m/s | **<0.001** | 0.61 (0.53-0.70) |
| 3-month follow-up | ≥0.50 m/s | **<0.001** | 0.62 (0.52-0.71) |
| 6-months follow-up | ≥0.50 m/s | **0.002** | 0.62 (0.50-0.73) |
| 12-months follow-up | ≥0.50 m/s | **<0.001** | 0.63 (0.51-0.76) |
| Entire follow-up | ≥0.50 m/s | **0.002** | 0.54 (0.38-0.70) |

**Supplementary Table 2B:** Best predictive cut-offs for the ability to wash in the “last week” and the “last month.”

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Best cut off (no. of days)** | **p-value**  **log rank test** | **AUC (95% CI)** |
| **No. of days able to wash yourself in the last week** | | | |
| 1-month follow-up | ≥6 | **0.015** | 0.57 (0.48-0.66) |
| 2-month follow-up | ≥6 | **0.009** | 0.58 (0.49-0.67) |
| 3-month follow-up | ≥5 | **0.010** | 0.60 (0.51-0.69) |
| 6-month follow-up | ≥5 | **0.027** | 0.57 (0.45-0.68) |
| 12-month follow-up | ≥5 | **0.023** | 0.59 (0.47-0.71) |
| Entire follow-up | ≥5 | **0.030** | 0.54 (0.40-0.69) |
| **No. of days able to wash yourself in the last month** | | | |
| 1-month follow-up | ≥21 | **<0.001** | 0.58 (0.49-0.67) |
| 2-month follow-up | ≥28 | **<0.001** | 0.58 (0.50-0.67 |
| 3-month follow-up | ≥23 | **<0.001** | 0.61 (0.52-0.70) |
| 6-month follow-up | ≥27 | **0.003** | 0.57 (0.46-0.69) |
| 12-months follow-up | ≥23 | **0.002** | 0.60 (0.48-0.72) |
| Entire follow-up | ≥23 | **0.002** | 0.56 (0.42-0.70) |

**Supplementary Table 3A:** Patient-reported outcomes and functional testing according to the best predictive cut-offs from a 2-month follow-up.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Patients able to walk 4m <2 days in the last week n=56** | **Patients able to walk 4m ≥2 days in the last week n=113** | **p-value** | **Patients able to walk 4m <14 days in the last month n=43** | **Patients able to walk 4m ≥14 days in the last month n=126** | **p-value** |
| Dyspnea NYHA ≥3, n (%) | 43 (77) | 50 (44) | **<0.001** | 33 (77) | 60 (48) | **<0.001** |
| Peripheral edema, n (%) | 22 (40) | 22 (20) | **0.005** | 19 (45) | 25 (20) | **0.001** |
| ECOG Performance Status ≥3, n (%) | 56 (100) | 75 (66) | **<0.001** | 43 (100) | 88 (70) | **<0.001** |
| Karnofsky Performance Status <40%, n (%) | 40 (71) | 17 (15) | **<0.001** | 28 (65) | 29 (23) | **<0.001** |
| Charlson Comorbidity Index (points) | 8 ± 2 | 8 ± 2 | 0.60 | 8 ± 2 | 8 ± 2 | 0.59 |
| Resting perceived dyspnea  (Borg scale, 0-10 points) | 5 (2-7) | 2 (1-5) | **<0.001** | 5 (3-7) | 3 (1-5) | **<0.001** |
| Resting perceived exertion  (Borg scale, 0-10 points) | 7 (5-8) | 5 (3-7) | 0.002 | 7 (5-9) | 5 (4-7) | **0.001** |
| Poor or very poor self-rated health, n (%) | 48 (91) | 79 (70) | **0.003** | 36 (88) | 91 (73) | **0.049** |
| Visual analogue scale appetite (mm) | 20 (5-50) | 35 (10-68) | 0.085 | 19 (5-50) | 35 (10-67) | **0.11** |
| Visual analogue scale pain (mm) | 23 (8-60) | 20 (0-50) | 0.35 | 25 (8-60) | 20 (0-50) | **0.41** |
| Hand-grip strength (N) | 211 ± 91 | 242 ± 80 | **0.039** | 206 ± 87 | 240 ± 83 | **0.038** |

Values are means ± SD for normal distribution, median and Interquartile Range (IQR) for non-normal distribution, or n (%). P-values for nominal variables refer to the two comparison groups. ECOG, Eastern Cooperative Oncology Group; mm, millimeter; N, Newton; NYHA, New York Heart Association

**Supplementary Table 3B:** Patient-reported outcomes and functional testing according to the best predictive cut-offs from 2-month follow-up.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Patients able to wash <6 days in the last week n=74** | **Patients able to wash ≥6 days in the last week n=95** | **p-value** | **Patients able to wash <28 days in the last month n=78** | **Patients able to wash ≥28 days in the last month n=91** | **p-value** |
| Dyspnea NYHA ≥3, n (%) | 59 (78) | 34 (36) | **<0.001** | 62 (80) | 31 (34) | **<0.001** |
| Peripheral edema, n (%) | 26 (36) | 18 (19) | **0.015** | 28 (36) | 16 (18) | **0.006** |
| ECOG Performance Status ≥3, n (%) | 72 (97) | 59 (62) | **<0.001** | 75 (96) | 56 (62) | **<0.001** |
| Karnofsky Performance Status <40%, n (%) | 45 (61) | 12 (13) | **<0.001** | 45 (58) | 12 (13) | **<0.001** |
| Charlson Comorbidity Index (points) | 8 ± 2 | 8 ± 2 | 0. 36 | 8 ± 2 | 8 ± 2 | 0.36 |
| Resting perceived dyspnea (Borg scale, 0-10 points) | 5 (2-7) | 2 (1-4) | **<0.001** | 5 (3-7) | 2 (1-4) | **<0.001** |
| Resting perceived exertion (Borg scale, 0-10 points) | 7 (4-9) | 5 (3-7) | **<0.001** | 7 (4-8) | 5 (3-7) | **<0.001** |
| Poor or very poor self-rated health, n (%) | 61 (86) | 66 (70) | **0.013** | 62 (83) | 65 (71) | 0.089 |
| Visual analog scale appetite (mm) | 24 (10-50) | 35 (10-78) | 0.17 | 25 (10-58) | 34 (10-76) | 0.36 |
| Visual analog scale pain (mm) | 20 (5-60) | 19 (0-50) | 0.40 | 23 (5-60) | 18 (0-50) | 0.34 |
| Hand-grip strength (N) | 202 ± 84 | 253 ± 79 | **<0.001** | 202 ± 84 | 253 ± 79 | **<0.001** |

Values are means ± SD for normal distribution, median and Interquartile Range (IQR) for non-normal distribution, or n (%). P-values for nominal variables refer to the two comparison groups. ECOG, Eastern Cooperative Oncology Group; mm, millimeter; N, Newton; NYHA, New York Heart Association;

**Supplementary Table 3C:** Patient-reported outcomes and functional testing according to the best predictive cut-off from the 2-month follow-up

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **4m gait speed ≥0.50 m/s**  **n=69** | **4m gait speed <0.50 m/s**  **n=100** | **p-value** |
| Dyspnea NYHA ≥3, n (%) | 23 (33) | 70 (70) | **<0.001** |
| Peripheral edema, n (%) | 10 (14) | 34 (34) | **0.004** |
| ECOG Performance Status ≥3, n (%) | 34 (49) | 97 (97) | **<0.001** |
| Karnofsky Performance Status <40%, n (%) | 5 (7) | 52 (52) | **<0.001** |
| Charlson Comorbidity Index (points) | 8 ± 2 | 8 ± 2 | 0.65 |
| Resting perceived dyspnea (Borg scale, 0-10 points) | 2 (0-5) | 4 (2-7) | **0.002** |
| Resting perceived exertion (Borg scale, 0-10 points) | 4 (2-7) | 7 (4-8) | **0.002** |
| Poor or very poor self-rated health, n (%) | 43 (62) | 84 (84) | **<0.001** |
| Visual analog scale appetite (mm) | 44 (15-80) | 20 (5-50) | **0.002** |
| Visual analog scale pain (mm) | 18 (0-50) | 25 (5-65) | 0.12 |
| Hand-grip strength (N) | 263 ± 68 | 209 ± 83 | **<0.001** |

Values are means ± SD for normal distribution, median and Interquartile Range (IQR) for non-normal distribution, or n (%). P-values for nominal variables refer to the two comparison groups. ECOG, Eastern Cooperative Oncology Group; mm, millimeter; N, Newton; NYHA, New York Heart Association